LT-2003 (Lumosa Therapeutics)

N/A

Report date: 2025/06/11 10:48:37

Base Information

Drug NameLT-2003 (Lumosa Therapeutics)
Drug Alias Nameanti-EGFR nanobody + CDase enzyme (Lumosa Therapeutics)EGFR targeted nanobody conjugated cytosine deaminase (Lumosa Therapeutics)LT-2003 (LTJ/Lumosa Therapeutics)EGFR targeted nanobody conjugated CDase enzyme (Lumosa Therapeutics)ECC-01
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionCytosine deaminase stimulantsEpidermal growth factor receptor erbB1 antagonistsAnticancer protein kinase inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1Cytosine deaminase
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTPG Biologics
China Registration ClassN/A

Develop Information

Active CompaniesLumosa Therapeutics Co Ltd
Inactive CompaniesTPG Biologics
Active IndicationsSolid tumoursPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A